Hayfin Capital Management
VC Fund
London, United Kingdom
Hayfin Capital Management is a VC fund in London focused on Health Care and Medical. Hayfin was founded in 2009 with the ambition of creating one of Europe’s leading investment platforms. They focus on delivering best-in-class risk-adjusted returns for their investors across four strategies: Direct Lending, Special Opportunities, High-Yield Credit and Securitized Credit. Hayfin is a London based firm with offices in Amsterdam,Frankfurt, Mardid, Paris and Luxembourg.They consider their selves value investors, generating differentiated return through hard work, insightful analysis and disciplined investing. Hayfin seeks to recruit and retain exceptionally talented professionals. They believe in being local in each of their markets, and that their diverse mix of nationalities, cultures and languages makes them more connected to these markets.Most of their team are industry generalists, with their edge lying in their origination networks and proven expertise in managing complex restructurings, workouts and liquidations. That said, they employ dedicated, specialist teams in the areas of healthcare (life sciences), shipping (maritime) and real estate, where they believe their focused expertise provides an advantage.They operate across all major European geographies with offices in London, Paris, Madrid, Frankfurt, Luxembourg and Tel Aviv, and have a growing presence in the United States with an office in New York.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 67%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Hayfin Capital Management invests in
Stages Hayfin Capital Management invests in
Countries Hayfin Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gonzalo Erroz
|
|||
Guy du Parc Braham
|
|||
Jatinder Singh
|
|||
Mark Tognolini
|
|||
Mikhael Botbol
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 11 (61%)
- Medical 7 (39%)
- Biotechnology 7 (39%)
- Therapeutics 3 (17%)
- Pharmaceutical 3 (17%)
Stage
- Debt Financing 5 (28%)
- Post-IPO Debt 4 (22%)
- Funding Round 3 (17%)
- Series F 1 (6%)
- Private Equity 1 (6%)
Country
- United States 9 (50%)
- Spain 1 (6%)
- Canada 1 (6%)
- France 1 (6%)
- Sweden 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Gonzalo Erroz
Partner
|
Partner | Total investments: 0 | Find email | |
|
Guy du Parc Braham
Chief Risk Officer
|
Chief Risk Officer | Total investments: 0 | Find email | |
|
Jatinder Singh
Chief Technology Officer
|
Chief Technology Officer | Total investments: 0 | Find email | |
|
Mark Tognolini
COO
|
COO | Total investments: 0 | Find email | |
|
Mikhael Botbol
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MiMedx Group
|
MiMedx Group is a biopharmaceutical company, develops, and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. MiMedx Group’s proprietary processingmethodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications, OrthoFlo, an amniotic fluid-derived allograft for homologous applications, Physio, a bone grafting material comprising 100% bone tissue with no added carrier, and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. It also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue, AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process, and AmnioFill, a cellular tissue matrix allograft that enhances healing. MiMedX Group's products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. It sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group began operation on February 28, 2008. It has its headquarters in Marietta in Georgia. | $300M / Post-IPO Debt / Jul 30, 2026 | |
Maha Capital
|
Maha Capital AB is a listed investment company focused on deploying capital across high-potential sectors. | $27M / Post-IPO Equity / Apr 02, 2026 | |
Grupo Uvesco
|
Uvesco is a group in the mass consumption and food distribution sector, in the process of expansion. The company is a benchmark in generating wealth and employment in the areas where it operates. | $547.5M / Debt Financing / Dec 24, 2025 | |
Novetude Sante Group
|
Novetude Sante is a French private higher education group, engaged in health careers training. | Private Equity / May 09, 2025 | |
Heartflow
|
HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on bloodflow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com. | $98M / Convertible Note / Mar 26, 2025 | |
Cosette Pharmaceuticals
|
Cosette Pharmaceuticals is a generic pharmaceutical company that specializes in the areas of dermatology and allergy. | Debt Financing / Jul 17, 2024 | |
Xeris Biopharma
|
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous,ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system. | $200M / Post-IPO Debt / Mar 06, 2024 | |
|
Heartflow
|
HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on bloodflow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com. | $215M / Series F / Apr 06, 2023 | |
KEO World
|
KEO World is an innovative FinTech helping Buyers and Suppliers accelerate business growth through all-digital inventory financing and B2B payment solutions. Headquartered in Miami, Florida, KEO operates in the U.S., Mexico and across LATAM by way of its Global Trade program. | $20M / Venture - Series Unknown / Jun 14, 2022 | |
ADMA Biologics
|
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiencydisease or who may be immune-suppressed for medical reasons.ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002. | $150M / Post-IPO Debt / Mar 24, 2022 | |
| See all 18 investments → | |||
Co-Investors
U.S. Venture Partners
3 deals together
Bain Capital Life Sciences
2 deals together
Capricorn Investment Group
2 deals together
Healthcor Management
2 deals together
Janus Henderson Investors
2 deals together
Martis Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hayfin Capital Management invest in?
Hayfin Capital Management invests primarily in Health Care, Medical and Biotechnology startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hayfin Capital Management?
Public channels for Hayfin Capital Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hayfin Capital Management?
The team at Hayfin Capital Management includes Gonzalo Erroz (Partner), Guy du Parc Braham (Chief Risk Officer) and Jatinder Singh (Chief Technology Officer), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
